ulevostinag   Click here for help

GtoPdb Ligand ID: 11972

Synonyms: compound 26 [PMID: 35332774] | MK-1454 | MK1454
Compound class: Synthetic organic
Comment: Ulevostinag (MK-1454) is a small molecule STING agonist that was developed as an anti-tumour agent [1]. It is a cyclic dinucleotide derivative.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 15
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 345.95
Molecular weight 710.05
XLogP -0.81
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Nc1[nH]c(=O)c2c(n1)n(cn2)[C@@H]1O[C@H]2[C@H]([C@H]1O[P@](=O)(S)OC[C@@H]1[C@@H](O[P@@](=O)(OC2)S)[C@@H]([C@@H](O1)n1cnc2c1ncnc2N)F)F
Isomeric SMILES Nc1ncnc2c1ncn2[C@H]1[C@@H](F)[C@@H]2O[P@](=O)(S)OC[C@@H]3[C@H]([C@@H](O[P@@](=O)(OC[C@H]2O1)S)[C@@H](O3)n1c2nc(N)[nH]c(=O)c2nc1)F
InChI InChI=1S/C20H22F2N10O9P2S2/c21-8-6-1-36-42(34,44)40-12-7(39-18(9(12)22)31-4-27-10-14(23)25-3-26-15(10)31)2-37-43(35,45)41-13(8)19(38-6)32-5-28-11-16(32)29-20(24)30-17(11)33/h3-9,12-13,18-19H,1-2H2,(H,34,44)(H,35,45)(H2,23,25,26)(H3,24,29,30,33)/t6-,7-,8-,9+,12-,13-,18-,19-,42-,43-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Intratumorally delivered ulevostinag is being evaluated in clinical trials in participants with advanced/metastatic solid tumours or lymphomas. The most advanced study is being conducted for head and neck squamous cell carcinoma (HNSCC).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03010176 Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Phase 1 Interventional Merck Sharp & Dohme Corp.
NCT04220866 Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Phase 2 Interventional Merck Sharp & Dohme Corp.